Pharmacokinetics of zimeldine in male alcoholics.
The pharmacokinetics of zimeldine, a 5-HT reuptake blocker with antidepressive effects, was studied after a single oral dose and after multiple oral administration in 19 alcoholic males, 10 with and 9 without chronic liver damage. The average plasma concentration of zimeldine as assessed by the AUC values (area under the plasma concentration-time curve) was significantly higher in the chronically liver damaged patients than in the patients without chronic liver damage. The plasma half-life of zimeldine was also significantly longer in the chronically liver damaged patients. There were no differences in the obtained pharmacokinetic parameters between the patients having nonchronic liver damage and healthy control subjects. The pharmacokinetics of the active metabolite norzimeldine (resulting from N-demethylation of zimeldine) showed no differences between the two groups of alcoholics and the healthy controls. The IgA values were significantly correlated to both the AUC and plasma half-life of zimeldine. No other correlation between clinical chemistry parameters and pharmacokinetic parameters of zimeldine and norzimeldine were found.
D000328:Adult; D000437:Alcoholism / Q000378:metabolism*; D001798:Blood Proteins / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D004798:Enzymes / Q000097:blood; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008108:Liver Diseases, Alcoholic / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D014280:Triglycerides / Q000097:blood; D015031:Zimeldine / Q000378:metabolism*
D001798:Blood Proteins; D004798:Enzymes; D014280:Triglycerides; D015031:Zimeldine; D002784:Cholesterol